Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ATXI

Avenue Therapeutics (ATXI)

Avenue Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATXI
DateTimeSourceHeadlineSymbolCompany
23/05/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
16/05/202422:30GlobeNewswire Inc.Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
15/05/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
15/05/202422:30GlobeNewswire Inc.Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
13/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
11/05/202406:53Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATXIAvenue Therapeutics Inc
11/05/202406:52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXIAvenue Therapeutics Inc
29/04/202422:00GlobeNewswire Inc.Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
24/04/202421:30GlobeNewswire Inc.Avenue Therapeutics Announces Reverse Stock SplitNASDAQ:ATXIAvenue Therapeutics Inc
25/03/202423:30GlobeNewswire Inc.Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024NASDAQ:ATXIAvenue Therapeutics Inc
19/03/202407:05GlobeNewswire Inc.Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
15/03/202423:15GlobeNewswire Inc.Avenue Therapeutics Receives Positive Listing Determination from NasdaqNASDAQ:ATXIAvenue Therapeutics Inc
11/03/202423:00GlobeNewswire Inc.Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
09/03/202408:31Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
09/03/202408:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
23/02/202400:30GlobeNewswire Inc.Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyNASDAQ:ATXIAvenue Therapeutics Inc
02/02/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
30/01/202400:00Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:ATXIAvenue Therapeutics Inc
25/01/202408:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATXIAvenue Therapeutics Inc
18/01/202409:05Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
12/01/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
12/01/202400:00GlobeNewswire Inc.Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceNASDAQ:ATXIAvenue Therapeutics Inc
09/01/202409:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
06/01/202401:15GlobeNewswire Inc.Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
05/01/202400:30GlobeNewswire Inc.Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolNASDAQ:ATXIAvenue Therapeutics Inc
03/01/202400:30GlobeNewswire Inc.Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
14/12/202308:03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXIAvenue Therapeutics Inc
14/12/202308:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
02/12/202300:30GlobeNewswire Inc.Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
29/11/202308:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ATXIAvenue Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXI

Your Recent History

Delayed Upgrade Clock